Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ: VANI )

1.290 +0.010 (+0.78%)
Streaming Delayed Price Updated: 3:39 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vivani Medical, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected... 
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is... 
Via Benzinga
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024
VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying
Via Benzinga
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or... 
Via Benzinga
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why GLP-1 Developer Vivani Medical's Stock Is Climbing
Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use
Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management. 
Via Benzinga
Exposures Product Safety
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use
Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research. 
Via Benzinga
VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024
VANI stock results show that Vivani Medical met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at TIDES Conference 2024
From Vivani Medical, Inc.
Via Business Wire
VANI Stock Earnings: Vivani Medical Beats EPS for Q4 2023
VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Exposures Product Safety
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.